Evidence-based treatment of children and adolescents with ADHD/DAMP with central stimulants;Evidensbaseret behandling af ADHD/DAMP-børn og unge med centralstimulerende medicin

Ugeskrift for Laeger

Volumn 163, Issue 8, 2001, Pages 1116-1121

  Dalsgaard, Søren ^a   Thomsen, Per Hove ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MAJOR CLINICAL STUDY; MOTOR CONTROL; REVIEW;

ADOLESCENT; ADOLESCENT PSYCHIATRY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD PSYCHIATRY; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 0035910999     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997: 36 (suppl 10): S85-121.
2. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857-64.
3. Lægemiddelstyrelsen DMA. Forbruget af Ritalin stiger. Notat af 18. juni 1999. København: Lægemiddelstyrelsen, 2000; 1-6.
4. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva, Switzerland: World Health Organization, 1993.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
6. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998; 59 (suppl 7): 24-30.
7. Sillesen I. Børnepsykiatrisk undersøgelse. I: Lier L, Isager T, Jørgensen OS, Larsen FW. Børnepsykiatri. 2. udg. København: Hans Reitzels Forlag, 1993: 128-56.
8. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991; 148: 564-77.
9. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry 1997; 36: 1065-79.
10. Abramowitz AJ, O'Leary SG. Behavioral interventions for the classroom-implications for students with ADHD. School Psychology Review 1991; 20: 220-34.
11. Wells KC, Pelham WE Jr, Kotkin RA, Hoza B, Abikoff HB, Abramowitz A et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol 2000; 28: 483-505.
12. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989; 28: 882-7.
13. March JS, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol 2000; 28; 527-41.
14. Abikoff H, Klein RG. Attention-deficit hyperactivity and conduct disorder: comorbidity and implications for treatment. J Consult Clin Psychol 1992; 60: 881-92.
15. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part II: Tactics. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 920-7.
16. Kristensen MB, Friis H, Rassing MR, eds. Lægemiddelkataloget 2000. København: Dansk Lægemiddel Information A/S, 2000.
17. Bradley C. The behavior of children recieving Benzedrine. Am J Psychiatry 1937; 94: 577-85.
18. Satterfield JH, Satterfield BT, Cantwell DP. Three-year multimodality treatment study of 100 hyperactive boys. J Pediatr 1981; 98: 650-5.
19. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 857-64.
20. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073-86.
21. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 908-19.
22. Dalsgaard S, Mortensen PB, Hansen N, Thomsen PH. Assessment of diagnostic criteria for ADHD from case records. Eur Child Adolesc Psychiatry 1999; 8 (suppl 2): 185.
23. Hinshaw SP, Heller T, McHale JP. Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphenidate. J Consult Clin Psychol 1992; 60: 274-81.
24. Mayes SD, Crites DL, Bixler EO, Humphrey FJ, Mattison RE. Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status. Dev Med Child Neurol 1994; 36: 1099-107.
25. Whalen CK, Henker B, Swanson JM, Granger D, Kliewer W, Spencer J. Natural social behaviors in hyperactive children: dose effects of methylphenidate. J Consult Clin Psychol 1987; 55: 187-93.
26. Barkley RA. The effects of methylphenidate on the interactions of pre-school ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry 1988; 27: 336-41.
27. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088-96.
28. Gadow KD, Sverd J, Sprafkin J, Nolan EE, Ezor SN. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995; 52: 444-55.
29. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette's syndrome. JAMA 1982; 247: 1168-9.
30. Papolus DF, Papolos J, Papolos D. The Bipolar Child: The Definitive and Reassuring Guide to Childhood's Most Misunderstood Disorder. New York: Broadway, 2000.
31. Hinshaw SP, Heller T, McHale JP. Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphenidate. J Consult Clin Psychol 1992; 60: 274-81.
32. Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1999; 38: 402-9.
33. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088-96.
34. Hughes CW, Emslie GJ, Crismon ML, Wagner KD, Birmaher B, Geller B et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1442-54.
35. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Conners CK et al. The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 908-19.
36. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997; 36: 589-96.
37. Kutcher SP, Fletcher J. Child & Adolescent Psychopharmacology. Nova Scotia, Canada: WB Saunders Co, 1997: 1.
38. Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998; 44: 269-73.
39. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104: e20.